The Effects of Vitamin D Supplementation in Newly Diagnosed Type 1 Diabetes Patients: Systematic Review of Randomized Controlled Trials

Elina Gregoriou; Ioannis Mamais; Irene Tzanetakou; Giagkos Lavranos; Stavri Chrysostomou

Article View

Abstract

The Review of Diabetic Studies,2017,14,2-3,260-268.

DOI:10.1900/RDS.2017.14.260

Published:August 2017

Type:Review Article

Authors:

Author(s) affiliations:

Elina Gregoriou¹, Ioannis Mamais², Irene Tzanetakou³, Giagkos Lavranos⁴, and Stavri Chrysostomou⁵

¹Department of Life Sciences, European University Cyprus, Engomi, NICOSIA-CYPRUS .

²Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, GREECE.

³Department of Life Sciences, European University of Cyprus, Nicosia, Cyprus, Engomi, NICOSIA-CYPRUS .

⁴Department of Health Sciences, European University Cyprus, Engomi, NICOSIA-CYPRUS .

⁵Department of Life Sciences, School of Science, European University Cyprus, Engomi, NICOSIA-CYPRUS.

Abstract:

Aim: The aim of this study was to examine the effects of vitamin D supplementation in patients newly diagnosed with type 1 diabetes (T1D) assessed by insulin needs and changes in glycemic indices, as evidenced by randomized controlled trials (RCTs). Methods: A total of 7 RCTs were retrieved from PubMed/Medline and EBSCO databases by MeSH term search, and were reviewed systematically. The RCTs included examined the effects of alphacalcidole (n = 2), cholecalciferol (n = 2), and calcitriol (n = 3) supplementation on changes in daily insulin dose (DID), fasting Cpeptide (FCP), stimulated C-peptide (SCP), and HbA1c. In total, 287 individuals, diagnosed with T1D within a period of 4 weeks to 1 year and aged between 5 to 38 years, were examined. Results: Significant positive effects on DID, FCP, and SCP levels were observed after supplementation with alphacalcidole and cholecalciferol, whereas supplementation with calcitriol showed no effect. Conclusion: Vitamin D supplementation in the form of alphacalcidole and cholecalciferol appears to be beneficial in the treatment of T1D patients by attenuating the natural history of the disease.